biotech
biotech Articles
Amgen Inc. (NASDAQ: AMGN) reported its fourth-quarter financial results after the markets closed on Thursday. This biotech giant posted $2.89 in earnings per share (EPS) and $5.97 billion in revenue,...
Published:
Last Updated:
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
Published:
Last Updated:
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.
Published:
Last Updated:
Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte.
Published:
Last Updated:
Pulmatrix saw its shares take a sharp downturn on Monday morning after the company announced that it had entered into a definitive agreement with several investors for a direct offering valued up to...
Published:
Last Updated:
Novan saw its shares get absolutely crushed on Friday after the company reported results from its late-stage treatment of acne vulgaris. Analysts took this opportunity to weigh in on the future of...
Published:
Last Updated:
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way.
Published:
Last Updated:
Ocular Therapeutix, Inc. (NASDAQ: OCUL) saw its shares take a dive on Tuesday after the company announced the pricing of its secondary offering. The company is pricing its 3.57 million shares at $7...
Published:
Last Updated:
It seems that analysts are taking the forefront and making calls on where the biopharma industry is going ahead of action by the Trump administration.
Published:
Last Updated:
The contract research organizations, or CROs, may offer a lot of value as companies look to bring in help from the outside in drug studies and development.
Published:
Last Updated:
Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
Published:
Last Updated:
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
Published:
Last Updated:
Not that many biotech and pharma companies were on the move Thursday, just one day before the inauguration. However, a few of the smaller caps made splash.
Published:
Last Updated:
The biotechs and emerging pharma have been under pressure from politicians attacking drug prices. That doesn't mean that there are not some big winners out there.
Published:
Last Updated: